Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tajikistan Health News.
Press releases published on July 24, 2025
Award-Winning Breckenridge Distillery Makes Bold Entry into Tequila with Launch of Casa Breck
GlobeNewswire
·
July 24, 2025
BRECKENRIDGE, Colo., July 24, 2025 (GLOBE NEWSWIRE) -- Breckenridge Distillery, an award-winning craft distillery and spirits brand by Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), proudly celebrates International Tequila Day with the launch of Casa …
Microbix Exhibiting & Presenting at ADLM
GlobeNewswire
·
July 24, 2025
MISSISSAUGA, Ontario, July 24, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it will be attending, exhibiting, and presenting at the Association …
INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer’s Association International Conference
GlobeNewswire
·
July 24, 2025
Boca Raton, July 24, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) announced today that additional analyses from its Phase 2 MINDFuL trial evaluating XPro™, a novel selective soluble TNF inhibitor, will be released in an oral presentation at the …
TCG Labs Soleil Raises an Additional $400 Million and Expands Global R&D Capabilities
GlobeNewswire
·
July 24, 2025
SAN FRANCISCO, July 24, 2025 (GLOBE NEWSWIRE) -- TCG Labs Soleil, a venture firm integrating dedicated capital with an in-house biotech R…
Biomea Fusion Appoints Julianne Averill to its Board of Directors
GlobeNewswire
·
July 24, 2025
SAN CARLOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced the appointment of Julianne Averill to its Board …
Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy
GlobeNewswire
·
July 24, 2025
Expedited Enrollment Surpassing 630 Targeted Participants Underscores the Strong Demand for a Therapy Focused on Vision Preservation Phase 3 ARCHER II Trial Design and Rationale to Be Presented at ASRS, a Leading Meeting for Retina Science and Innovation …
MediPharm Labs Expands Leading CBN Oil Portfolio with The Launch of New Nighttime Inhaler
GlobeNewswire
·
July 24, 2025
TORONTO, July 24, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specializing in precision-based cannabinoids, is pleased to announce it has …
Javvy Protein Coffee Officially Launches, Redefining Javy Coffee Protein United States & Canada
GlobeNewswire
·
July 24, 2025
New York City, NY, July 24, 2025 (GLOBE NEWSWIRE) -- A new era of functional wellness beverages begins with the highly anticipated launch of Javvy Protein Coffee, a groundbreaking product that redefines the traditional coffee experience. Developed with a …
MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials
GlobeNewswire
·
July 24, 2025
LA JOLLA, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), today provides an …
Biodesix to Report Second Quarter 2025 Financial Results on August 7, 2025
GlobeNewswire
·
July 24, 2025
LOUISVILLE, Colo., July 24, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the second quarter ended June 30, 2025 after the close of trading on …
Aicuris Enrolled Last Participant in Pivotal Trial with Pritelivir to Treat Refractory Herpes Simplex Infection in Immunocompromised Patients
GlobeNewswire
·
July 24, 2025
Wuppertal, Germany, July 24, 2025 - Aicuris Anti-infective Cures AG today announced the completion of patient enrollment in its pivotal Phase 3 trial, PRIOH-1, evaluating pritelivir for the treatment of refractory and/or treatment resistant herpes simplex …
First half of 2025: Solid growth, investments and pipeline progress pave the way for two key launches in H2
GlobeNewswire
·
July 24, 2025
Group net sales grow by 6.3%* to EUR 14.0 billion, driven by Human Pharma (EUR 11.3 billion) and Animal Health (EUR 2.6 billion) Regulatory submissions underway for zongertinib and nerandomilast, with launches expected in H2 2025 Strategic investments in …
Citryll Announces Formation of Scientific Advisory Board
GlobeNewswire
·
July 24, 2025
CITRYLL ANNOUNCES FORMATION OF SCIENTIFIC ADVISORY BOARD Board comprises world-renowned experts in biology, immunology and pathology Oss, Netherlands – 24 July 2025 – Citryll, a biotech company pioneering a transformative approach to treating immune- …
AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALS
GlobeNewswire
·
July 24, 2025
PRESS RELEASE AB SCIENCE HAS RECEIVED APPROVAL FROM SEVERAL EUROPEAN COUNTRIES TO INITIATE THE CONFIRMATORY PHASE 3 STUDY OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS THIS APPROVAL FOLLOWS PROTOCOL VALIDATION BY THE EMA AND FDA AUTHORIZATION Paris, July …
AB Science a obtenu l'autorisation de plusieurs pays européens pour initier l’étude confirmatoire de phase 3 avec le masitinib dans la SLA
GlobeNewswire
·
July 24, 2025
COMMUNIQUÉ DE PRESSE AB SCIENCE A OBTENU L'AUTORISATION DE PLUSIEURS PAYS EUROPÉENS POUR INITIER L’ETUDE CONFIRMATOIRE DE PHASE 3 AVEC LE MASITINIB DANS LA SCLEROSE LATERALE AMYOTROPHIQUE CETTE AUTORISATION FAIT SUITE A LA VALIDATION DU PROTOCOLE PAR L’EMA …
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
GlobeNewswire
·
July 24, 2025
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris PARIS, France, July 24, 2025 – 07:30 a.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused …
argenx to Report Half Year 2025 Financial Results and Second Quarter Business Update on July 31, 2025
GlobeNewswire
·
July 24, 2025
July 24, 2025 Amsterdam, the Netherlands – argenx (Euronext …
Local Plastic Surgeon in Paramus New Jersey, Dr. Andrew Nouri Educates Patients on Insurance Coverage for Medically Necessary Breast Reduction
GlobeNewswire
·
July 24, 2025
Paramus, NJ, July 23, 2025 (GLOBE NEWSWIRE) -- For many women, large breasts are not just a cosmetic concern, they’re a medical one. Chronic back, neck, and shoulder pain, rashes under the breasts, painful grooves from bra straps, posture problems, and …
Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million
GlobeNewswire
·
July 24, 2025
Carlsbad, CA, July 23, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, …